SEC Form RW filed by Landos Biopharma Inc.

$LABP
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $LABP alert in real time by email
RW 1 d653520drw.htm RW RW

Landos Biopharma, Inc.

P.O. Box 11239

Blacksburg, VA 24062

May 23, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

RE:

Landos Biopharma, Inc.

Withdrawal of Registration Statement on Form S-3

File No. 333-263836

Ladies and Gentlemen:

Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Landos Biopharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s registration statement on Form S-3 (File No. 333-263836), together with the exhibits thereto, which was filed on March 24, 2022, as amended by that certain Amendment No. 1 to the registration statement on Form S-3, filed with the SEC on August 11, 2022 (the “Registration Statement”), as of the date hereof or at the earliest practicable date hereafter. The Registration Statement was declared effective by the Commission on August 15, 2022, but no securities have been issued or sold under the Registration Statement.

Accordingly, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.

Should you have any questions regarding this request, please do not hesitate to contact counsel to the Company, Madison Jones of Cooley LLP at (202) 728-7087, or in her absence, Paul Alexander at (202) 776-2118.

 

Sincerely,
Landos Biopharma, Inc.
By:  

/s/ Fabio Cataldi    

Name:   Fabio Cataldi
Title:   Authorized Officer

 

cc:

Kevin Cooper (Cooley LLP)

Eric Blanchard (Cooley LLP)

Madison Jones (Cooley LLP)

Paul Alexander (Cooley LLP)

Get the next $LABP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LABP

DatePrice TargetRatingAnalyst
4/12/2022$30.00 → $1.40Buy → Hold
Jefferies
1/3/2022$15.00 → $7.00Neutral
JP Morgan
11/16/2021$20.00 → $16.00Outperform → Market Perform
SVB Leerink
10/20/2021$45.00Buy
Craig-Hallum
10/19/2021$50.00Buy
HC Wainwright & Co.
9/23/2021$39.00Buy
JonesTrading
7/30/2021$33.00 → $35.00Outperform
Raymond James
More analyst ratings

$LABP
Press Releases

Fastest customizable press release news feed in the world

See more
  • AbbVie Completes Acquisition of Landos Biopharma

    -   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ:LABP). With the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family), which is currently in Phase 2 for the treatment of moderate to severe UC (NEXUS study; NCT05785715). NLRX1 regulates immunometabolism and inflammation,

    $ABBV
    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie

    MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ:LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you. In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right

    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

    Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC)NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates

    $ABBV
    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LABP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LABP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LABP
SEC Filings

See more

$LABP
Leadership Updates

Live Leadership Updates

See more
  • Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie

    MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ:LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you. In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right

    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results

    Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2023. "We continued to advance and execute the NX-13 Phase 2 clinical program (NEXUS) during the second quarter. We have activated sites in the US and are actively recruiting and screening pa

    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

    NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. "Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos' Board," said Gregory Oakes, President and CEO of Landos. "Dr. Batycky has a proven track record, and we look forward to her contributions as we execute upon our focused strategy in immunology." Dr. Batycky brings with her over 25 years of global drug development experience in the biopharmaceutical in

    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LABP
Financials

Live finance-specific insights

See more
  • Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

    Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Significant Optionality for Omilancor, LABP-104 and Four Promising Pre-Clinical Programs Secures Additional $16.7 Million Investment Disciplined Financial Approach Expected to Maintain Cash Runway into First Half of 2025 Company to Host Investor Call at 8:00 AM ET NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical

    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal Enrollment for Phase 2 Clinical Study of Omilancor in Crohn's Disease and Phase 1b Study of NX-13 in UC Initiated Dosing for LABP-104 in Healthy Volunteers in October 2021 with Results Expected in 1H 2022 Corporate Update Conference Call Scheduled for 8:00 am ET Today BLACKSBURG, Va., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clin

    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Landos Biopharma to Host Corporate Update Call

    BLACKSBURG, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ:LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021. Following the release of the financial results, Landos will host a live webcast at 8:00 am ET. The webcast can be accessed through the Company's investor relations website at https://ir.landosbiopharma.com/, or by dialing 1-877-317-6789 (Toll Free) or 1-412-317-6789 (International) and asking to join the Landos Corporate Update call. The webcast will be archived and be available for replay on the Company's investor relations website. About Landos Biopha

    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LABP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more